Moderna Concludes FDA Submission For Its COVID-19 Shot In Adolescents, Kids

Reuters reported that Moderna Inc MRNA had made required submissions to the FDA for emergency use authorization of its COVID-19 vaccine in adolescents and children.
An advisory panel of experts to the U.S. drug regulator will meet in June to review the request.
Related: FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA.
The company is seeking approval for its vaccines in adolescents aged 12 to 17 years, children aged six to 11, and those between six years and six months.
The company said the submissions for all three groups were made on May 9.
Although the FDA approves Moderna's vaccine for use in adults 18 years and older, its use in the younger age groups has hit a roadblock as the agency asked for more safety data.
Australia, Canada, and the European Union have approved the vaccine for use in six- to 17-year-olds.
In April, the company sought U.S. authorization for its COVID shot in children under six years.
Price Action: MRNA shares are up 4.76% at $129.30 during the market session on the last check Thursday.
Photo by Spencer Davis from Pixabay

Momentum5.08

GrowthNot Available

QualityNot Available

Value69.76

Short

Medium

Long